Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02082210
Title A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02114-3117 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Tennessee Oncology PLLC Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field